《美股業績》藥廠渤健(BIIB.US)下調全年盈測 老年痴呆症藥僅800人使用
美國渤健藥廠(Biogen)(BIIB.US)公布第三季業績。按年由盈轉虧,蝕6,810萬美元,對上年度同期純利11.35億美元。每股季度攤薄虧損47美仙,經調整後為盈利4.36美元,好過市場預期的3.97美元。季度收人按年升0.9%至25.3億美元。
公司預期全年度每股經調整盈利介乎14.5至15美元,低於早前指引的15至16美元,亦低於市場預期的15.26美元。公司與日本衛采開發的亞斯海默症藥Leqembi目前有約800人使用,與公司目標明年3月有1萬名病人使用有很大距離。
該股昨日(8日)跌5.7%報231.69美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.